Two IDH inhibitors, ivosedinib (an IDH1 inhibitor) and enasedinib (an IDH2 inhibitor) demonstrated efficacy against gliomas, cholangiocarcinomas, and AML in clinical trials [167,168,169,170]. Here, IDH1 is linked to central nervous system cancer.